Key Topic Videos | MYLOTARG®▽(gemtuzumab ozogamicin) | PfizerPro UK
Haematologica August 2021
Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midst - ScienceDirect
Common mutations in de novo and secondary AML. A number of clonal blood... | Download Scientific Diagram
Recently approved therapies in acute myeloid leukemia: A complex treatment landscape - ScienceDirect
A single-cell survey of cellular hierarchy in acute myeloid leukemia | Journal of Hematology & Oncology | Full Text
Outcome of patients with either de novo or secondary AML after alloSCT... | Download Scientific Diagram
Characterization and Prognosis of Secondary Acute Myeloid Leukemia in an Asian Population: AML With Antecedent Hematological Disease Confers Worst Outcomes, Irrespective of Cytogenetic Risk | Anticancer Research
Redefining prognostication of de novo cytogenetically normal acute myeloid leukemia in young adults | Blood Cancer Journal
Decitabine shows comparable OS to standard induction chemotherapy and better safety in patients with AML
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics | Leukemia
How do doctors tell de novo acute myeloid leukemia (de novo AML), AML-MRC, and tAML apart? - YouTube
Overall survival time in de novo AML and in t-AML. t-AML,... | Download Scientific Diagram
Biology of secondary leukemia
Acute Myeloid Leukemia | Oncohema Key
Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1 - Modern Pathology
UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia | Leukemia
Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06 | Haematologica
Frontiers | Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells
What is AML? | MDS Foundation
Survival of de novo acute myeloid leukemia at MD Anderson (1970-2017)... | Download Scientific Diagram
IJMS | Free Full-Text | Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress
Characterization and Prognosis of Secondary Acute Myeloid Leukemia in an Asian Population: AML With Antecedent Hematological Disease Confers Worst Outcomes, Irrespective of Cytogenetic Risk | Anticancer Research
